This article will be permanently flagged as inappropriate and made unaccessible to everyone. Are you certain this article is inappropriate? Excessive Violence Sexual Content Political / Social
Email Address:
Article Id: WHEBN0018493882 Reproduction Date:
InChI=1S/C19H28N2O2S/c1-14(2)24(22,23)21-13-15(3)17-8-10-19(11-9-17)18-6-4-16(12-20)5-7-18/h4-7,14-15,17,19,21H,8-11,13H2,1-3H3 N Key:AIALBPYHYGYYRB-UHFFFAOYSA-N N
LY-404,187 (or LY404187) is an ampakine (or "AMPA receptor potentiator") developed by Eli Lilly and Company.[1] It is a member of the biarylpropylsulfonamide class of ampakines.[2]
LY-404,187 has been demonstrated to enhance cognitive function in animal studies, and has also shown effects suggesting antidepressant action as well as having possible application in the treatment of schizophrenia, Parkinson's disease and ADHD. These effects appear to be mediated through multiple mechanisms of action secondary to AMPA receptor potentiation, with a prominent effect seen in research being increased levels of BDNF in the brain.[3] It may therefore be continued on to human trials, although Eli Lilly has developed a whole family of biarylpropylsulfonamide derivatives and it is unclear at this stage which compound is most likely to be selected for further development.[4][5]
Oxygen, Chlorine, Fluorine, Sicily, Periodic table
Alcohol, Kava, Xenon, Cocaine, Morphine
Dark matter, Rice University, Italy, Columbia University, Gran Sasso National Laboratory
Diamond, Graphite, Solar system, Coal, /anolanthanide Chemistry
Glutamate, Sulfur, Ibotenic acid, Ethanol, Evans blue
Glutamate, Ibotenic acid, Ethanol, Evans blue, Xenon
Sulfur, Ethanol, Xenon, Carbon, Hydrogen